Attitudes about human papillomavirus vaccine among family physicians.

University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.
Journal of Pediatric and Adolescent Gynecology (Impact Factor: 1.81). 01/2006; 18(6):391-8. DOI: 10.1016/j.jpag.2005.09.004
Source: PubMed

ABSTRACT Human papillomavirus (HPV) vaccines will soon be available for clinical use, and the effectiveness of vaccine delivery programs will depend largely upon whether providers recommend the vaccine. The objectives of this study were to examine family physicians' attitudes about HPV immunization and to identify predictors of intention to recommend immunization.
Cross-sectional survey instrument assessing provider and practice characteristics, knowledge about HPV, attitudes about HPV vaccination, and intention to administer two hypothetical HPV vaccines.
Surveys were mailed to a national random sample of 1,000 American Academy of Family Physicians (AAFP) members.
Intention to administer two hypothetical HPV vaccines (a cervical cancer/genital wart vaccine and a cervical cancer vaccine) to boys and girls of different ages.
One hundred fifty-five surveys (15.5%) were returned and 145 were used in the final sample. Participants reported higher intention to recommend both hypothetical HPV vaccines to girls vs. boys (P < 0.0001) and to older vs. younger adolescents (P < 0.0001). They were more likely to recommend a cervical cancer/genital wart vaccine than a cervical cancer vaccine to boys and girls (P < 0.001). Variables independently associated with intention (P < 0.05) included: female gender of provider, knowledge about HPV, belief that organizations such as the AAFP would endorse vaccination, and fewer perceived barriers to vaccination.
Female gender, knowledge about HPV, and attitudes about vaccination were independently associated with family physicians' intention to recommend HPV vaccines. Vaccination initiatives directed toward family physicians should focus on modifiable predictors of intention to vaccinate, such as HPV knowledge and attitudes about vaccination.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Background: Little is known about physicians' human papillomavirus (HPV) vaccine recommendations for males while the Advisory Committee on Immunization Practices' (ACIP) permissive guidelines for male vaccination were in effect. The purpose of this study was to examine and explore factors associated with U.S. physicians' HPV vaccine recommendations to early (ages 11-12), middle (13-17), and late adolescent/young adult (18-26) males. Methods: Nationally representative samples of family physicians and pediatricians were selected in 2011 (n=1,219). Physicians reported the frequency with which they recommended HPV vaccine to male patients ("always" [>75% of the time] vs. other) for each age group. Statistically significant predictors of vaccine recommendation were identified using multivariable logistic regression. Results: The prevalence of physicians reporting they "always" recommended HPV vaccination for males was 10.8% for ages 11-12, 12.9% for ages 13-17, and 13.2% for ages 18-26. Pediatrician specialty and self-reported early adoption of new vaccines were significantly associated with recommendation for all patient age groups. Additionally, physician race and patient payment method were associated with physician recommendations to patients ages 11-12, and patient race was associated with recommendations to ages 13-17 and 18-26. Conclusions: Less than 15% of physicians surveyed reported "always" recommending HPV vaccine to male patients following national guidelines for permissive vaccination. Vaccine financing may have affected physicians' vaccine recommendations. Impact: If these recommendation practices continue following the ACIP's routine recommendation for males in October 2011, then interventions designed to increase recommendations should target family physicians and possibly utilize early adopters to encourage support of HPV vaccination guidelines.
    Cancer Epidemiology Biomarkers & Prevention 07/2014; 23(10). DOI:10.1158/1055-9965.EPI-14-0344 · 4.32 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Human papilloma virus (HPV) occurs in women of all age groups, and causes cervical, anal, vaginal, vulvar, penile and oropharyngeal cancers. The aim of the study was to discover what nurses know about HPV infection, testing and vaccination and to determine vaccine practice of their daughters and perceived barriers.
    Asian Pacific journal of cancer prevention: APJCP 10/2014; 15(18):7693-702. DOI:10.7314/APJCP.2014.15.18.7693 · 1.50 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background: A physician’s recommendation is the most effective published method of motivating HPV vaccination initiation. The emergency department (ED) is the ‘public health safety net’, and often the only access to care for underserved populations. Recommendation of the HPV vaccine by emergency medicine (EM) physicians has great potential to improve vaccination rates among subpopulations who do not have access to routine medical care. We assessed willingness of EM physicians to recommend the vaccine, target high-risk women, and perceived barriers to vaccination in the ED. Methods: A cross sectional study using an 11-item survey with a response format utilizing a validated Likert scale, was used to assess physician attitudes of 50 EM physicians (19 EM attending physicians and 31 resident physicians) towards recommending the HPV vaccine in an ED setting to age eligible patients. Results: 67.4% stated they would recommend the vaccine, 23.9% were neutral, and 8.7% would not recommend the vaccine to age eligible patients in the ED. 41% noted lack of adequate reimbursement for vaccination as a barrier to vaccination in the ED (p <.05). Physicians were comfortable targeting women at high risk for cervical cancer for vaccination (p <.05). Conclusion: Local EM physicians are comfortable targeting high-risk women for HPV vaccination in an ED setting. Support of EM physicians in the national effort to improve HPV vaccine uptake is an important step in eradicating a largely preventable yet lethal cancer.
    142nd APHA Annual Meeting and Exposition 2014; 11/2014